323TiP - EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC)
| Autor: | Martin Jimenez, M., Bachelot, T., Barrios, C., Blackwell, K., Chia, S., De Laurentiis, M., Hurvitz, S., Janni, W., Kaufman, B., Loi, S., Schmid, P., Slamon, D., Hazell, K., Mondal, S., Shilkrut, M., Germa, C., Hortobagyi, G. |
|---|---|
| Zdroj: | In Annals of Oncology September 2017 28 Supplement 5:v107-v107 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|